Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -21.38% is 33% above its 5-year average of -31.98%, near the high end of its 5-year range (-52.96%–-20.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 41.52% above its 12-month average of -36.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -21.38%.
RETURN ON EQUITY (ROE)
-21.38%
RETURN ON EQUITY (ROE) AVG TTM
-36.56%
RETURN ON EQUITY (ROE) AVG 3Y
-36.17%
RETURN ON EQUITY (ROE) AVG 5Y
-31.98%
RETURN ON EQUITY (ROE) AVG 10Y
-58.64%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.52%
CURRENT VS 3Y AVG
+40.90%
CURRENT VS 5Y AVG
+33.14%
CURRENT VS 10Y AVG
+63.54%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 623 covered companies
CURRENT VS SECTOR MEDIAN
+46.82%
vs the sector median at left
Anavex Life Sciences Corp.
Market Cap
$151.98M
Return on Equity (ROE)
-21.38%
TTM Avg
-36.56%
3Y Avg
-36.17%
5Y Avg
-31.98%
Market Cap
$151.10M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$152.17M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$149.98M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$148.36M
Return on Equity (ROE)
-397.38%
TTM Avg
-1100.28%
3Y Avg
-310.11%
5Y Avg
-250.84%
Market Cap
$155.42M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$155.86M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$147.97M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$158.30M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $151.98M | -21.38% | -36.56% | -36.17% | -31.98% |
| Codexis, Inc. (CDXS)vs › | $151.10M | -93.22% | -92.28% | -73.94% | -53.80% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.17M | -155.34% | -168.75% | -117.97% | -104.46% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.98M | -183.44% | -114.28% | -67.72% | -46.03% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | -397.38% | -1100.28% | -310.11% | -250.84% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | -59.40% | -255.06% | -160.44% | -112.56% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | 13.51% | 15.58% | 15.05% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -266.86% | 156.76% | 98.17% | -694.29% |
| Inogen, Inc. (INGN)vs › | $158.30M | -14.07% | -16.23% | -27.66% | -19.01% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | -131.85% | -36.69% | -135.43% | -129.92% |
ROE
-21.4%
ROA
-20.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -21.38% |
| 2026-03-31 | -28.01% |
| 2025-12-31 | -31.55% |
| 2025-09-30 | -48.89% |
| 2025-06-30 | -52.96% |
| 2025-03-31 | -47.26% |
| 2024-12-31 | -41.92% |
| 2024-09-30 | -35.76% |
| 2024-06-30 | -32.00% |
| 2024-03-31 | -30.03% |
| 2023-12-31 | -31.83% |
| 2023-09-30 | -33.49% |
| 2023-06-30 | -35.19% |
| 2023-03-31 | -36.33% |
| 2022-12-31 | -37.05% |
| 2022-09-30 | -33.67% |
| 2022-06-30 | -30.12% |
| 2022-03-31 | -28.39% |
| 2021-12-31 | -27.97% |
| 2021-09-30 | -25.14% |
| 2021-06-30 | -20.46% |
| 2021-03-31 | -37.54% |
| 2020-12-31 | -59.49% |
| 2020-09-30 | -96.49% |
| 2020-06-30 | -98.03% |
| 2020-03-31 | -97.73% |
| 2019-12-31 | -93.37% |
| 2019-09-30 | -121.09% |
| 2019-06-30 | -150.19% |
| 2019-03-31 | -160.86% |
| 2018-12-31 | -117.97% |
| 2018-09-30 | -85.17% |
| 2018-06-30 | -71.29% |
| 2018-03-31 | -78.19% |
| 2017-12-31 | -56.26% |
| 2017-09-30 | -55.50% |
| 2017-06-30 | -63.18% |
| 2017-03-31 | -62.58% |
| 2016-12-31 | -72.63% |
| 2016-09-30 | -233.61% |
| 2016-06-30 | -177.05% |
| 2016-03-31 | -160.92% |
| 2015-12-31 | -132.93% |
| 2015-09-30 | -94.53% |
| 2015-06-30 | -234.20% |
| 2015-03-31 | -281.13% |
| 2014-06-30 | -62.87% |
| 2014-03-31 | -45.20% |
